*** This Study was terminated on May 17, 2018 due to Safety monitoring concerns. It was felt the risk (liver inflammation in some patients) did not favor any potential benefit for the Study Drug.  Please consider other Alzheimer's Clinical Trials if you are eligible.

What follows is a brief summary of the Janssen EARLY trial for individuals with "pre-clinical" aymptomatic Alzheimer's pathology. 

  • Drug administration -- daily oral

  • Age range -- 60-85

  • CDR range -- global score 0, only

  • Study Duration -- 4.5 years

  • Target population -- amyloid PET or CSF positive asymptomatic individuals

  • Mechanism of action -- blocks formation of active beta amyloid protein (BACE inhibition)

  • Randomization split -- 50:50 active : placebo

  • Type(s) of imaging -- brain MRI, amyloid PET, tau PET

For more details on this specific trial, visit:


A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060